BioCardia (BCDA) Competitors

BioCardia logo
$0.77 -0.02 (-2.06%)
Closing price 04:00 PM Eastern
Extended Trading
$0.78 +0.00 (+0.52%)
As of 06:49 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

BCDA vs. RNTX, ONCY, APLM, INKT, and ALPS

Should you buy BioCardia stock or one of its competitors? BioCardia's main competitors and comparable companies include Rein Therapeutics (RNTX), Oncolytics Biotech (ONCY), Apollomics (APLM), MiNK Therapeutics (INKT), and ALPS Group Inc Ordinary Share (ALPS). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does BioCardia compare to Rein Therapeutics?

Rein Therapeutics (NASDAQ:RNTX) and BioCardia (NASDAQ:BCDA) are both small-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their analyst recommendations, risk, earnings, dividends, media sentiment, institutional ownership, valuation and profitability.

In the previous week, BioCardia had 3 more articles in the media than Rein Therapeutics. MarketBeat recorded 7 mentions for BioCardia and 4 mentions for Rein Therapeutics. Rein Therapeutics' average media sentiment score of 1.17 beat BioCardia's score of 0.98 indicating that Rein Therapeutics is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Rein Therapeutics
1 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
BioCardia
0 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Rein Therapeutics' return on equity of 0.00% beat BioCardia's return on equity.

Company Net Margins Return on Equity Return on Assets
Rein TherapeuticsN/A N/A -69.69%
BioCardia N/A -912.37%-236.99%

BioCardia has higher revenue and earnings than Rein Therapeutics. BioCardia is trading at a lower price-to-earnings ratio than Rein Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Rein TherapeuticsN/AN/A-$49.87M-$1.72N/A
BioCardia$60K198.89-$8.23M-$0.52N/A

Rein Therapeutics has a beta of 1.47, suggesting that its stock price is 47% more volatile than the broader market. Comparatively, BioCardia has a beta of 0.69, suggesting that its stock price is 31% less volatile than the broader market.

Rein Therapeutics presently has a consensus target price of $6.00, indicating a potential upside of 1,583.50%. BioCardia has a consensus target price of $25.00, indicating a potential upside of 3,071.78%. Given BioCardia's higher possible upside, analysts clearly believe BioCardia is more favorable than Rein Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Rein Therapeutics
1 Sell rating(s)
1 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.25
BioCardia
1 Sell rating(s)
1 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00

90.9% of Rein Therapeutics shares are held by institutional investors. Comparatively, 20.6% of BioCardia shares are held by institutional investors. 1.5% of Rein Therapeutics shares are held by company insiders. Comparatively, 17.4% of BioCardia shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Summary

Rein Therapeutics beats BioCardia on 8 of the 14 factors compared between the two stocks.

How does BioCardia compare to Oncolytics Biotech?

BioCardia (NASDAQ:BCDA) and Oncolytics Biotech (NASDAQ:ONCY) are both small-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their profitability, media sentiment, risk, valuation, dividends, analyst recommendations, earnings and institutional ownership.

20.6% of BioCardia shares are held by institutional investors. Comparatively, 6.8% of Oncolytics Biotech shares are held by institutional investors. 17.4% of BioCardia shares are held by insiders. Comparatively, 4.7% of Oncolytics Biotech shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

BioCardia currently has a consensus target price of $25.00, indicating a potential upside of 3,071.78%. Oncolytics Biotech has a consensus target price of $5.00, indicating a potential upside of 1,207.19%. Given BioCardia's higher probable upside, analysts plainly believe BioCardia is more favorable than Oncolytics Biotech.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
BioCardia
1 Sell rating(s)
1 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00
Oncolytics Biotech
1 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00

BioCardia has a beta of 0.69, suggesting that its stock price is 31% less volatile than the broader market. Comparatively, Oncolytics Biotech has a beta of 1.26, suggesting that its stock price is 26% more volatile than the broader market.

BioCardia has higher revenue and earnings than Oncolytics Biotech. BioCardia is trading at a lower price-to-earnings ratio than Oncolytics Biotech, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
BioCardia$60K198.89-$8.23M-$0.52N/A
Oncolytics BiotechN/AN/A-$28.76M-$0.32N/A

In the previous week, BioCardia had 1 more articles in the media than Oncolytics Biotech. MarketBeat recorded 7 mentions for BioCardia and 6 mentions for Oncolytics Biotech. BioCardia's average media sentiment score of 0.98 beat Oncolytics Biotech's score of -0.19 indicating that BioCardia is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
BioCardia
0 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Oncolytics Biotech
0 Very Positive mention(s)
1 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
1 Very Negative mention(s)
Neutral

Oncolytics Biotech's return on equity of 0.00% beat BioCardia's return on equity.

Company Net Margins Return on Equity Return on Assets
BioCardiaN/A -912.37% -236.99%
Oncolytics Biotech N/A N/A -477.70%

Summary

BioCardia beats Oncolytics Biotech on 8 of the 12 factors compared between the two stocks.

How does BioCardia compare to Apollomics?

Apollomics (NASDAQ:APLM) and BioCardia (NASDAQ:BCDA) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their risk, earnings, dividends, profitability, valuation, analyst recommendations, institutional ownership and media sentiment.

BioCardia has a consensus price target of $25.00, indicating a potential upside of 3,071.78%. Given BioCardia's stronger consensus rating and higher probable upside, analysts clearly believe BioCardia is more favorable than Apollomics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Apollomics
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
BioCardia
1 Sell rating(s)
1 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00

19.1% of Apollomics shares are owned by institutional investors. Comparatively, 20.6% of BioCardia shares are owned by institutional investors. 17.4% of BioCardia shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

In the previous week, BioCardia had 6 more articles in the media than Apollomics. MarketBeat recorded 7 mentions for BioCardia and 1 mentions for Apollomics. Apollomics' average media sentiment score of 1.45 beat BioCardia's score of 0.98 indicating that Apollomics is being referred to more favorably in the media.

Company Overall Sentiment
Apollomics Positive
BioCardia Positive

Apollomics' return on equity of 0.00% beat BioCardia's return on equity.

Company Net Margins Return on Equity Return on Assets
ApollomicsN/A N/A N/A
BioCardia N/A -912.37%-236.99%

Apollomics has a beta of 1.57, indicating that its stock price is 57% more volatile than the broader market. Comparatively, BioCardia has a beta of 0.69, indicating that its stock price is 31% less volatile than the broader market.

BioCardia has lower revenue, but higher earnings than Apollomics.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Apollomics$8.50M5.65-$10.94MN/AN/A
BioCardia$60K198.89-$8.23M-$0.52N/A

Summary

BioCardia beats Apollomics on 8 of the 13 factors compared between the two stocks.

How does BioCardia compare to MiNK Therapeutics?

MiNK Therapeutics (NASDAQ:INKT) and BioCardia (NASDAQ:BCDA) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their profitability, valuation, risk, dividends, institutional ownership, media sentiment, analyst recommendations and earnings.

MiNK Therapeutics' return on equity of 0.00% beat BioCardia's return on equity.

Company Net Margins Return on Equity Return on Assets
MiNK TherapeuticsN/A N/A -103.82%
BioCardia N/A -912.37%-236.99%

MiNK Therapeutics presently has a consensus target price of $44.00, indicating a potential upside of 374.14%. BioCardia has a consensus target price of $25.00, indicating a potential upside of 3,071.78%. Given BioCardia's higher possible upside, analysts clearly believe BioCardia is more favorable than MiNK Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
MiNK Therapeutics
1 Sell rating(s)
1 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.25
BioCardia
1 Sell rating(s)
1 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00

2.9% of MiNK Therapeutics shares are held by institutional investors. Comparatively, 20.6% of BioCardia shares are held by institutional investors. 20.4% of MiNK Therapeutics shares are held by company insiders. Comparatively, 17.4% of BioCardia shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

MiNK Therapeutics has a beta of 0.49, indicating that its stock price is 51% less volatile than the broader market. Comparatively, BioCardia has a beta of 0.69, indicating that its stock price is 31% less volatile than the broader market.

BioCardia has higher revenue and earnings than MiNK Therapeutics. MiNK Therapeutics is trading at a lower price-to-earnings ratio than BioCardia, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
MiNK TherapeuticsN/AN/A-$12.49M-$2.25N/A
BioCardia$60K198.89-$8.23M-$0.52N/A

In the previous week, MiNK Therapeutics had 7 more articles in the media than BioCardia. MarketBeat recorded 14 mentions for MiNK Therapeutics and 7 mentions for BioCardia. BioCardia's average media sentiment score of 0.98 beat MiNK Therapeutics' score of 0.53 indicating that BioCardia is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
MiNK Therapeutics
2 Very Positive mention(s)
0 Positive mention(s)
5 Neutral mention(s)
1 Negative mention(s)
1 Very Negative mention(s)
Positive
BioCardia
0 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Summary

BioCardia beats MiNK Therapeutics on 7 of the 13 factors compared between the two stocks.

How does BioCardia compare to ALPS Group Inc Ordinary Share?

BioCardia (NASDAQ:BCDA) and ALPS Group Inc Ordinary Share (NASDAQ:ALPS) are both small-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their institutional ownership, profitability, earnings, analyst recommendations, valuation, risk, media sentiment and dividends.

In the previous week, BioCardia had 6 more articles in the media than ALPS Group Inc Ordinary Share. MarketBeat recorded 7 mentions for BioCardia and 1 mentions for ALPS Group Inc Ordinary Share. BioCardia's average media sentiment score of 0.98 beat ALPS Group Inc Ordinary Share's score of 0.92 indicating that BioCardia is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
BioCardia
0 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
ALPS Group Inc Ordinary Share
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

BioCardia currently has a consensus target price of $25.00, suggesting a potential upside of 3,071.78%. Given BioCardia's stronger consensus rating and higher possible upside, analysts clearly believe BioCardia is more favorable than ALPS Group Inc Ordinary Share.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
BioCardia
1 Sell rating(s)
1 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00
ALPS Group Inc Ordinary Share
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

BioCardia has a beta of 0.69, meaning that its stock price is 31% less volatile than the broader market. Comparatively, ALPS Group Inc Ordinary Share has a beta of -0.08, meaning that its stock price is 108% less volatile than the broader market.

20.6% of BioCardia shares are held by institutional investors. Comparatively, 27.9% of ALPS Group Inc Ordinary Share shares are held by institutional investors. 17.4% of BioCardia shares are held by insiders. Comparatively, 0.8% of ALPS Group Inc Ordinary Share shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

ALPS Group Inc Ordinary Share's return on equity of 0.00% beat BioCardia's return on equity.

Company Net Margins Return on Equity Return on Assets
BioCardiaN/A -912.37% -236.99%
ALPS Group Inc Ordinary Share N/A N/A N/A

ALPS Group Inc Ordinary Share has higher revenue and earnings than BioCardia. BioCardia is trading at a lower price-to-earnings ratio than ALPS Group Inc Ordinary Share, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
BioCardia$60K198.89-$8.23M-$0.52N/A
ALPS Group Inc Ordinary Share$4.86M7.63-$2.01M$0.264.50

Summary

BioCardia beats ALPS Group Inc Ordinary Share on 8 of the 14 factors compared between the two stocks.

Get BioCardia News Delivered to You Automatically

Sign up to receive the latest news and ratings for BCDA and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding BCDA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

BCDA vs. The Competition

MetricBioCardiaBiotechnology IndustryHealthcare SectorNASDAQ Exchange
Market Cap$11.93M$4.03B$7.72B$11.68B
Dividend YieldN/A3.63%2.47%4.51%
P/E Ratio-1.4825.9032.4827.27
Price / Sales194.8015.668.385.63
Price / CashN/A22.7220.8521.62
Price / Book12.874.164.443.72
Net Income-$8.23M-$23.99M$3.51B$394.03M
7 Day Performance-16.24%-8.45%-6.54%-6.07%
1 Month Performance-16.10%-6.55%-4.93%-7.38%
1 Year Performance-40.16%-6.56%-1.68%-7.46%

BioCardia Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
BCDA
BioCardia
2.9089 of 5 stars
$0.77
-2.1%
$25.00
+3,138.3%
-35.4%$11.93M$60KN/A21
RNTX
Rein Therapeutics
2.3579 of 5 stars
$0.59
-5.0%
$6.00
+916.9%
-70.8%$53.56MN/AN/A10
ONCY
Oncolytics Biotech
1.6723 of 5 stars
$0.38
-6.4%
$5.00
+1,209.6%
-63.6%$53.46MN/AN/A29
APLM
Apollomics
0.8967 of 5 stars
$18.19
-0.3%
N/A-23.0%$53.20M$8.50MN/A15
INKT
MiNK Therapeutics
2.9082 of 5 stars
$10.01
-2.8%
$44.00
+339.6%
-22.7%$52.53MN/AN/A15

Related Companies and Tools


This page (NASDAQ:BCDA) was last updated on 11/18/2026 by MarketBeat.com Staff.
From Our Partners